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Clinical Research Article
Background: Postoperative nausea and vomiting (PONV) continues to be a major problem, because PONV is 
associated with delayed recovery and prolonged hospital stay. Although the PONV guidelines recommended the use 
of 5-hydroxy-tryptamine (5-HT3) receptor antagonists as the first-line prophylactic agents in patients categorized as 
high-risk, there are few studies comparing the efficacies of ondansetron, ramosetron, and palonosetron. The aim of 
present study was to compare the prophylactic antiemetic efficacies of three 5HT3 receptor antagonists in high-risk 
patients after laparoscopic surgery.
Methods: In this prospective, randomized, double-blinded trial, 109 female nonsmokers scheduled for elective 
laparoscopic surgery were randomized to receive intravenous 4 mg ondansetron (n = 35), 0.3 mg ramosetron (n 
= 38), or 75 μg palonosetron (n = 36) before anesthesia. Fentanyl-based intravenous patient-controlled analgesia 
was administered for 48 h after surgery. Primary antiemetic efficacy variables were the incidence and severity of 
nausea, the frequency of emetic episodes during the first 48 h after surgery, and the need to use a rescue antiemetic 
medication.
Results: The overall incidence of nausea/retching/vomiting was lower in the palonosetron (22.2%/11.1%/5.6%) 
than in the ondansetron (77.1%/48.6%/28.6%) and ramosetron (60.5%/28.9%/18.4%) groups. The rescue antiemetic 
therapy was required less frequently in the palonosetron group than the other groups (P < 0.001). Kaplan-Meier analysis 
showed that the order of prophylactic efficacy in delaying the interval to use of a rescue emetic was palonosetron, 
ramosetron, and ondansetron. 
Conclusions: Single-dose palonosetron is the prophylactic antiemetics of choice in high-risk patients undergoing 
laparoscopic surgery. (Korean J Anesthesiol 2013; 64: 517-523)
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Introduction
Postoperative nausea and vomiting (PONV) continues to be 
a major problem although avoiding PONV is a high priority for 
patients and physicians. Apart from patient discomfort, PONV 
is associated with adverse effects, such as delayed recovery and 
prolonged hospital stay. Although rare, postoperative morbidities 
including wound dehiscence, pulmonary aspiration, bleeding, 
and dehydration that can occur if vomiting is prolonged [1]. 
Established patient-specific risk factors for PONV include female 
gender, nonsmoking, and a history of motion sickness or PONV, 
whereas nonspecific factors are postoperative opioids use and 
type of surgery such as laparoscopy [2-4]. 
Ondansetron was the first commercially available 5-hydroxy-
tryptamine (5-HT3) receptor antagonist, thereafter granisetron, 
dolasetron, tropisetron, ramosetron, and palonosetron were 
introduced. Many studies have confirmed that this class of 
antiemetics exhibited better prophylactic efficacies compared 
with the older traditional drugs including droperidol, perphena-
zine, or metoclopramide [5-7]. A number of studies have been 
conducted to compare the prophylactic antiemetic efficacies 
among 5-HT3 receptor antagonists [8-12]. To date, however, 
there are few clinical studies comparing the prophylactic 
efficacies of ondansetron, ramosetron, and palonosetron in 
high-risk patients with PONV. 
The aim of this prospective, randomized, double-blinded 
trial was to compare the prophylactic antiemetic efficacies 
of ondansetron, ramosetron, and palonosetron in high-risk 
patients with fentanyl-based PCA after laparoscopic surgery. 
Our hypothesis was that three 5HT3 receptor antagonists show 
different antiemetic efficacies when used prophylactically. 
Materials and Methods
Our study was conducted from July 2010 to June 2011 and 
109 patients were enrolled. The inclusion criteria were as 
follows: 1) American Society of Anesthesiologists physical 
status I-II, 2) female patient aged 20-65 years, 3) nonsmoker, 
4) history of motion sickness or previous PONV, 5) elective 
laparoscopic surgery, and 6) use of postoperative intravenous 
patient-controlled analgesia (IV-PCA) using fentanyl. The 
exclusion criteria were: impairment of bowel motility, diabetes, 
pregnancy or lactation, administration of an antiemetic 
medication or steroids within 24 h before surgery, the presence 
of a cardiovascular or respiratory disease, obesity (body mass 
index > 35 kg/m2), or renal or hepatic dysfunction. The plan 
of the study was reviewed and approved by the Institutional 
Review Board of Yonsei University Health Systems) and written 
informed consent was obtained from all patients. 
Randomization and blinding
Using computer-generated random numbers, the hospital 
pharmacy that prepared the study drugs assigned patients into 
one of 3 active treatment groups on the morning of the day of 
surgery. Of the 109 patients, 35 were randomized to receive 
4 mg ondansetron (ondansetron group), 38 mg to 0.3 mg 
ramosetron (ramosetron group), or 36 μg to 75 μg palonosetron 
(palonosetron group). Each study drug was mixed with saline 
to a total volume of 3 ml in an unlabeled syringe and was 
intravenously administered just prior to induction of anesthesia. 
All patients, surgeons, anesthesiologists, and nurses involved in 
the study were blinded to group allocation and every precaution 
was taken to maintain the double-blind conditions. 
General anesthesia
No patient received premedication. Intraoperative moni-
toring included electrocardiography, blood pressure measure-
ment, peripheral oxygen saturation (SpO2), and end-tidal CO2 
tension (ETco2). General anesthesia was induced using 2 mg/kg 
of propofol and 1 μg/kg of remifentanil infusion. After tracheal 
intubation using 0.6 mg/kg of rocuronium, anesthesia was 
maintained with sevoflurane in 50% oxygen/air. Sevoflurane 
concentration was adjusted to ensure an equal depth of 
anesthesia during surgery as assessed by the bispectral index 
(BIS; BIS A-1050 Monitor, Aspect Medical Systems, Newton, 
MA, USA), which was held between 40-60. Remifentanil was 
administered for supplemental intraoperative analgesia and 
its dose was adjusted to maintain blood pressure and a heart 
rate within 20% of baseline values. Patients emerging from 
anesthesia were managed in the postanesthetic care unit and 
in the ward by an anesthesiologist blinded to group allocation. 
All intraoperative variables including total amounts of infused 
remifentanil, administered fluid, urine output, and estimated 
blood loss were also counted by blinded anesthesiologist.
Intravenous Patient-Controlled Analgesia (IV-PCA)
IV-PCA devices (Ambix anaplus, E-Wha Fresenius Kabi 
Inc., Gunpo, Republic of Korea) with 0.2 μg/kg/ml of fentanyl 
were commenced at the end of surgery with each device 
programmed to deliver 1 ml/h as a background infusion and 1 
ml per demand with a 15 min lockout time over a 48 h period. 
Outcome measures
Primary antiemetic efficacy variables were the incidence and 
severity of nausea, the frequency of emetic episodes during the 
first 48 h after surgery, and the need to use a rescue antiemetic 
519www.ekja.org
Korean J Anesthesiol Kim et al.
medication. Nausea was defined as a subjective desire to vomit, 
but without expulsive muscular movements. Nausea was 
scored on an 11-point verbal rating scale from 0 (no nausea) to 
10 (worst possible nausea): severity was scored as mild (1-3), 
moderate (4-6), or severe (7-10) [13]. Retching was defined 
as an expulsive movement of the stomach muscles without 
expulsion of stomach contents [14]; both retching and vomiting 
were considered to be emetic episodes [14,15].
If patients complained of moderate to severe nausea, had 
any emetic episode, or requested a rescue drug, 20 mg of 
propofol was administered repeatedly for treatment in the 
PACU. When rescue antiemetics were needed in the ward, 
10 mg of metoclopramide was given. If PONV occurred more 
than 6 h after surgery, 4 mg of ondansetron or/and 4 mg of 
dexamethasone was/were administered at the discretion of 
attending anesthesiologists. Dexamethasone administration 
was not repeated more than once for 8 h. The interval to the 
first administration of a rescue antiemetic commenced at the 
end of surgery. Postoperative nausea and emetic episodes were 
assessed for 48 h after surgery by 2 independent investigators 
blinded to patient group. Patients were assessed over 5 time 
periods: 0-1 h, 1-6 h, 6-24 h, and 24-48 h after surgery. IV-
PCA was discontinued when severe nausea persisted despite 
treatment with rescue antiemetics and/or at the patient’s 
request. Patients complaining of pain after discontinuation of 
IV-PCA were given 30 mg of intravenous ketorolac.
Secondary efficacy variables included postoperative pain 
intensity and the total amount of fentanyl administered via 
IV-PCA. Pain intensity was measured using an 11-point VRS 
ranging from 0 (no pain) to 10 (worst pain imaginable) at 1 h, 6 h, 
24 h, and 48 h after surgery.
The most frequently reported side-effects of 5-HT3 including 
headache, dizziness, and drowsiness were also assessed during 
the study period [14].
Statistics
Sample size was calculated with reference to the results of a 
study comparing the effects of ramosetron and ondansetron on 
PONV associated with the use of IV-PCA in highly susceptible 
patients [9]. We calculated that the inclusion of 35 patients 
per group would afford an 80% chance of detection of a 20% 
reduction in the incidence of PONV using the Fisher’s exact 
test with a type I error of 0.05. All statistical analyses were 
performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, 
USA). The Shapiro-Wilk test was used to ensure that data were 
normally distributed. Patient characteristics and intra- and 
post-operative variables were analyzed by two-tailed ANOVA. 
Table 1. Patients and Intraoperative Characteristics
Ondansetron group
(n = 35)
  Ramosetron group
(n = 38)
   Palonosetron group
(n = 36)
P value
Age (yr)
Weight (kg)
Height (cm)
Duration of surgery (min)
Administered fluid (ml)
Total remifentanil (µg)
Urine output (ml)
Blood loss (ml)
53.3 ± 10.9
64.5 ± 5.7
162.1 ± 5.8
147.3 ± 88.3
1403 ± 1024
896 ± 223
333 ± 416
163 ± 133
  54.8 ± 11.1 
  65.0 ± 11.3
  163.6 ± 6.1
  153.6 ± 82.5
  1478 ± 882
  872 ± 218
  361 ± 399
  222 ± 186
   54.3 ± 10.5
   67.6 ± 9.0
   164.5 ± 4.9
   169.9 ± 87.6
   1614 ± 773
   905 ± 275
   231 ± 206
   273 ± 262
0.542
0.290
0.193
0.522
0.606
0.513
0.423
0.180
Data are presented as mean ± SD. There were no significant differences among groups.
Table 2. Postoperative Nausea, Retching, and Vomiting 
 Ondansetron group
 (n = 35)
   Ramosetron group 
   (n = 38)
   Palonosetron group 
   (n = 36)
P value
Nausea free
Nausea severity
    0-1 h (mild/moderate/severe)
    1-6 h (mild/moderate/severe)
    6-24 h (mild/moderate/severe)
    24-48 h (mild/moderate/severe)
Retching
Vomiting
Rescue antiemetic
Postanesthetic care unit stay (min)
8 (22.9)
1/1/0
9/6/7
10/9/7
6/2/0
17 (48.6)
10 (28.6)
19 (54.3)
46.6 ± 16.2
   15 (39.5)†
   1/3/0
   5/8/3
   8/5/7
   4/4/0
  11 (28.9)
   7 (18.4)
   13 (34.2)
   42.1 ± 9.5
   28 (77.8)*
   0/0/0
     0/1/1*
     1/3/2*
     1/0/0*
   4 (11.1)*
   2 (5.6)*
   4 (11.1)*
   46.4 ± 14.0
0.001
0.072
0.007
0.010
0.021
0.001
0.014
<0.001
0.262
Data are mean ± SD or numbers of patients (%). *P < 0.05 compared with the other two groups, †P < 0.05 compared with ondansetron group.
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Intergroup differences in nonparametric variables were 
compared using the Kruskal-Wallis test followed by Dunn’s 
multiple comparisons. Categorical data were compared using 
the chi-squared test or the Fisher’s exact test. The Kaplan-Meier 
method was used to determine the intervals to the first use of 
rescue antiemetic in the 3 groups; the curves were compared 
using the log rank test (Mantel-Cox). A P value < 0.05 was 
considered statistically significant.
Results 
No patient withdrew from the study. Neither patient cha-
racteristics nor intraoperative data differed among the 3 groups 
(Table 1).
The number of nausea-free patients was greater in the 
palonosetron group than in the other 2 groups during the 48 h 
study period (Table 2). The number of nausea-free patients was 
also greater in the ramosetron group than in the ondansetron 
group overall. During the first hour after surgery, the overall 
number of patients who experienced postoperative nausea 
was low and not significantly different among the groups. The 
rescue antiemetic was used less frequently in the palonosetron 
group than in the other 2 groups. Patients who were given the 
rescue antiemetic were censored and Kaplan-Meier analysis 
of the interval to first rescue antiemetic showed a significant 
intergroup difference (Fig. 1) between the palonosetron and 
ondansetron (P < 0.001), palonosetron and ramosetron (P < 
0.001), and ondansetron and ramosetron (P = 0.042) groups. Thus, 
the order of prophylactic efficacy in prolonging the time to use a 
rescue emetic was palonosetron, ramosetron, and ondansetron.
Six patients (17.1%) in the ondansetron group, 5 (14.3%) 
in the ramosetron group, and none (0%) in the palonosetron 
group (P = 0.041) requested disconnection of the IV-PCA pumps 
because of intractable nausea and/or vomiting after surgery 
mostly within 12 h. 
Pain scores and the total amounts of fentanyl administered 
via IV-PCA were similar in the three groups during 48 h after 
surgery (Fig. 2). The 3 groups were also similar in terms of 
the number of patients who experienced adverse events 
postoperatively (Table 3).
Fig. 1. Kaplan-Meier analysis of the intervals before administering 
the first dose of rescue antiemetic in the palonosetron, ondansetron, 
and ramosetron groups. Significant differences were observed 
between the palonosetron and ondansetron (P < 0.001), palono-
setron and ramosetron (P < 0.001), and ondansetron and ramosetron 
(P = 0.042) groups.
Fig. 2. (A) Postoperative pain scores (VAS) at 1 h, 6 h, 24 h, and 48 h after surgery in the palonosetron, ondansetron, and ramosetron groups. 
Data are shown as box plots with ranges (whiskers), interquartile ranges (boxes), medians (solid lines), and means (bold lines). There was no 
difference in VAS pain score among the groups during the study period. (B) Total amounts of fentanyl administered via intravenous patient-
controlled analgesia (IV-PCA) in the 3 groups during 48 h after surgery. Data are shown as mean with SD.
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Discussion
This prospective, randomized, double-blinded trial com-
pared the prophylactic antiemetic efficacies of ondan setron, 
ramosetron, and palonosetron in high-risk patients. Palono-
setron was superior to ondansetron or ramosetron when used 
prophylactically to reduce the incidence and severity of PONV 
and to delay the use of rescue antiemetics.
Consistent with previous findings [9], we observed very 
high incidences of PONV (80%) despite the prophylactic use 
of ondansetron. This is mainly due to the patient’s factor. 
All study patients were at high-risk because they had at 
least 4 predictors of PONV: female gender, nonsmoker, use 
of postoperative opioids, and history of motion sickness or 
previous PONV. The incidence of PONV increases exponentially 
from 10% when no risk factor is present to 79% when 4 risk 
factors are all present [4,14]. Laparoscopic surgery is also highly 
susceptible to PONV because abdominal gas insufflation may 
stretch mechanoreceptors of the intestine and consequently 
activate 5-HT3 receptors via serotonin release [16]. Another 
explanation for the frequent PONV in our results is the use of 
fentanyl-based IV-PCA, especially the use of basal infusion 
with relatively low demand capacity of fentanyl in our settings. 
Adding a basal infusion to IV-PCA could be more convenient in 
surgery and more effective in reducing resting pain than bolus 
demand only, but it may be associated with a greater risk of 
PONV. In addition, other reasons for unsatisfactory antiemetic 
effects of ondansetron given prophylactically are the timing of 
administration [17], the dose of ondansetrone [18], and CYP2D6 
alleles polymorphisms [19].
Although ondansetron has been used to prevent PONV 
[20,21], there are conflicting results about its effect on preventing 
IV-PCA related PONV, which were not clinically satisfactory 
[22,23]. In our results, there was no difference among the groups 
in terms of the number of patients who experienced nausea 
and emetic episodes in the first hour after surgery. However, 
after that period, ondansetron did not reduce fentanyl-based 
IV-PCA related nausea and emetic episodes. Ramosetron, a 
newer 5-HT3 antagonist, has been reported to be an effective 
antiemetic in patients undergoing various types of surgery. The 
elimination half-life of ramosetron (5.8 ± 1.2 h) is longer than 
that of ondansetron (3.8 ± 1.0 h) [24]. Two recent, randomized 
studies compared the prophylactic antiemetic efficacies of 
ondansetron and ramosetron in patients receiving opioid-based 
PCA [9,10] The former of the 2 studies found that the incidence 
of nausea was similar in the 2 groups, but that ramosetron 
decreased the severity of nausea and the incidence of vomiting, 
resulting in a reduced need for antiemetic rescue treatment [9]. 
The latter of the 2 studies showed that the rate of PONV and 
the use of rescue antiemetics were lower in the patients who 
received ramosetron than in patients who received ondansetron 
[10]. The present study showed that the ramosetron group 
had more patients who presented nausea-free postoperatively 
compared with the ondansetron group. During first 1-6 h after 
surgery, fewer patients who had emetic episodes were also in 
the ramosetron group than in the ondansetron group, despite 
the similar severity of nausea. In addition, Kaplan-Meier 
analysis revealed that ramosetron significantly prolonged the 
time to use a rescue emetic compared with ondansetron, which 
is attributable to failure of prophylaxis. 
Palonosetron, the latest 5-HT3 receptor antagonist intro-
duced in 2003, has been proven to be effective when used 
to prevent emesis associated with chemotherapy [25]. The 
minimum effective dose of palonosetron was 75 μg and the 
drug has been approved by the United States Food and Drug 
Administration (FDA) for PONV prophylaxis [26,27]. We found 
that palonosetron exerted a greater prophylactic effect than did 
either ondansetron or ramosetron. Kaplan-Meier analysis also 
showed that the efficacy of palonosetron was superior to that 
of the other 2 drugs. The greater efficacy of palo no setron may 
be attributable to the fact that the binding affinity to the 5-HT3 
receptor is 30 times higher than that of either ondansetron or 
ramosetron and/or to the extended half-life of palonosetron 
(approximately 40 h, thus 4-10-fold longer than that of the 
older antagonists) [28]. However, these properties do not 
entirely explain the higher efficacy of palonosetron relative 
to ondansetron or ramosetron. If efficacy was attributable 
to potency alone, ondansetron or ramosetron could be 
administered at higher doses. If half-life was all-important, 
other drugs with shorter half-lives could be injected more often. 
Table 3. Postoperative Side Effects 
Ondansetron group
(n = 35)
Ramosetron group
   (n = 38)
Palonosetron group
    (n = 36)
P value
Pruritus
Headache
Dizziness
Fever
Chest tightness
2 (5.7)
3 (8.6)
3 (8.6)
1 (2.9)
1 (2.9)
   1 (2.6)
   1 (2.6)
   2 (5.3)
   2 (5.3)
   0 (0.0)
    3 (8.3)
    2 (5.6)
    4 (11.1)
    2 (5.6)
    1 (5.6)
0.217
0.362
0.231
0.695
0.711
Data are presented as number of patients (%). There were no significant differences among groups.
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However, administration of ondansetron for more than 24 h 
after chemotherapy did not prolong the emesis-free interval 
afforded by the use of palonosetron [29], suggesting that the 
longer half-life of palonosetron does not explain the greater 
antiemetic efficacy of the drug when given within 24 h after 
surgery. Palonosetron may be unique in terms of allosteric 
interaction with and binding cooperativity to 5-HT3 receptors 
[30]. Moreover, binding of palonosetron to the receptors 
and thereby inhibiting calcium influx is not easily reversible, 
suggesting that palonosetron uniquely triggers 5-HT3 receptor 
internalization and induces prolonged inhibition of receptor 
function [30].
Our study has several limitations. First, we did not include 
a placebo control group to evaluate the baseline incidence of 
PONV as we considered it unethical to withhold prophylactic 
antiemetic drugs in patients at high risk for PONV. Second, patient 
satisfaction was not an end-point. Third, combination therapy 
has been shown to be more effective to treat or prevent PONV, 
especially in high-risk patients. For example, corticosteroids 
such as dexamethasone are frequently combined with agents of 
other drug classes, such as metoclopramide or 5-HT3 antagonists, 
resulting in significant improvements in response. Future 
research should assess the use of drug combinations to prevent 
PONV in high-risk patients; the work should also evaluate drug 
cost-effectiveness. It is also necessary to assess the efficacy of 
antiemetic drugs in the treatment of established PONV.
In conclusion, a single intravenous injection of 75 μg of palo-
nosetron was more effective in preventing PONV and reduced 
the need to use a rescue antiemetic compared to an injection 
of 4 mg of ondansetron or 0.3 mg of ramosetron in high-risk 
patients who were scheduled for laparoscopic surgery with 
fentanyl-based postoperative pain management.
References
1. Habib AS, Gan TJ. Pharmacotherapy of postoperative nausea and 
vomiting. Expert Opin Pharmacother 2003; 4: 457-73.
2. Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, et al. 
Consensus guidelines for managing postoperative nausea and 
vomiting. Anesth Analg 2003; 97: 62-71.
3. Eberhart LH, Hogel J, Seeling W, Staack AM, Geldner G, Georgieff M. 
Evaluation of three risk scores to predict postoperative nausea and 
vomiting. Acta Anaesthesiol Scand 2000; 44: 480-8.
4. Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A sim plified 
risk score for predicting postoperative nausea and vomiting: con-
clusions from cross-validations between two centers. Anesthe sio-
logy 1999; 91: 693-700.
5. Kovac AL. Prevention and treatment of postoperative nausea and 
vomiting. Drugs 2000; 59: 213-43.
6. Chatterjee S, Rudra A, Sengupta S. Current concepts in the manage-
ment of postoperative nausea and vomiting. Anesthesiol Res Pract 
2011; 2011: 748031.
7. Alon E, Himmelseher S. Ondansetron in the treatment of post-
operative vomiting: a randomized, double-blind comparison with 
droperidol and metoclopramide. Anesth Analg 1992; 75: 561-5.
8. Naguib M, el Bakry AK, Khoshim MH, Channa AB, el Gammal M, 
el Gammal K, et al. Prophylactic antiemetic therapy with ondan-
setron, tropisetron, granisetron and metoclopramide in patients 
undergoing laparoscopic cholecystectomy: a randomized, double-
blind comparison with placebo. Can J Anaesth 1996; 43: 226-31.
9. Choi YS, Shim JK, Yoon do H, Jeon DH, Lee JY, Kwak YL. Effect 
of ramosetron on patient-controlled analgesia related nausea 
and vomiting after spine surgery in highly susceptible patients: 
comparison with ondansetron. Spine (Phila Pa 1976) 2008; 33: E602-
6.
10. Hahm TS, Ko JS, Choi SJ, Gwak MS. Comparison of the prophylactic 
anti-emetic efficacy of ramosetron and ondansetron in patients at 
high-risk for postoperative nausea and vomiting after total knee 
replacement. Anaesthesia 2010; 65: 500-4.
11. Choi YS, Shim JK, Ahn SH, Kwak YL. Efficacy comparison of ramo-
setron with ondansetron on preventing nausea and vomiting in 
high-risk patients following spine surgery with a single bolus of 
dexamethasone as an adjunct. Korean J Anesthesiol 2012; 62: 543-7.
12. Lee JW, Park HJ, Choi J, Park SJ, Kang H, Kim EG. Comparison of 
ramosetron's and ondansetron's preventive anti-emetic effects in 
highly susceptible patients undergoing abdominal hysterectomy. 
Korean J Anesthesiol 2011; 61: 488-92.
13. Boogaerts JG, Vanacker E, Seidel L, Albert A, Bardiau FM. Assessment 
of postoperative nausea using a visual analogue scale. Acta 
Anaesthesiol Scand 2000; 44: 470-4.
14. Apfel CC, Roewer N, Korttila K. How to study postoperative nausea 
and vomiting. Acta Anaesthesiol Scand 2002; 46: 921-8.
15. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, et al. A 
factorial trial of six interventions for the prevention of postoperative 
nausea and vomiting. N Engl J Med 2004; 350: 2441-51.
16. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth 
Analg 2006; 102: 1884-98.
17. Tang J, Wang B, White PF, Watcha MF, Qi J, Wender RH. The effect 
of timing of ondansetron administration on its efficacy, cost-
effectiveness, and cost-benefit as a prophylactic antiemetic in the 
ambulatory setting. Anesth Analg 1998; 86: 274-82.
18. Figueredo E, Canosa L. Prophylactic ondansetron for postoperative 
emesis. Meta-analysis of its effectiveness in patients with previous 
history of postoperative nausea and vomiting. Acta Anaesthesiol 
Scand 1999; 43: 637-44.
19. Candiotti KA, Birnbach DJ, Lubarsky DA, Nhuch F, Kamat A, Koch 
WH, et al. The impact of pharmacogenomics on postoperative 
nausea and vomiting: do CYP2D6 allele copy number and poly-
morphisms affect the success or failure of ondansetron prophylaxis? 
Anesthesiology 2005; 102: 543-9.
20. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, dose-
response, and safety of ondansetron in prevention of postoperative 
nausea and vomiting: a quantitative systematic review of rando-
mized placebo-controlled trials. Anesthesiology 1997; 87: 1277-89.
21. White PF, Watcha MF. Postoperative nausea and vomiting: pro-
phylaxis versus treatment. Anesth Analg 1999; 89: 1337-9.
22. Dresner M, Dean S, Lumb A, Bellamy M. High-dose ondansetron 
523www.ekja.org
Korean J Anesthesiol Kim et al.
regimen vs droperidol for morphine patient-controlled analgesia. 
Br J Anaesth 1998; 81: 384-6.
23. Millo J, Siddons M, Innes R, Laurie PS. Randomised double-blind 
comparison of ondansetron and droperidol to prevent post-
operative nausea and vomiting associated with patient-controlled 
analgesia. Anaesthesia 2001; 56: 60-5.
24. Rabasseda X. Ramosetron, a 5-HT3 receptor antagonist for the 
control of nausea and vomiting. Drugs Today (Barc) 2002; 38: 75-89.
25. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, 
Cartmell A, et al. Improved prevention of moderately emetogenic 
chemotherapy-induced nausea and vomiting with palonosetron, 
a pharmacologically novel 5-HT3 receptor antagonist: results of a 
phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-
82.
26. Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C. A randomized, 
double-blind study to evaluate the efficacy and safety of three 
different doses of palonosetron versus placebo in preventing post-
operative nausea and vomiting over a 72-hour period. Anesth Analg 
2008; 107: 439-44.
27. Candiotti KA, Kovac AL, Melson TI, Clerici G, Joo Gan T. A rando-
mized, double-blind study to evaluate the efficacy and safety of 
three different doses of palonosetron versus placebo for preventing 
postoperative nausea and vomiting. Anesth Analg 2008; 107: 445-
51.
28. Aapro MS. Palonosetron as an anti-emetic and anti-nausea agent in 
oncology. Ther Clin Risk Manag 2007; 3: 1009-20.
29. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor 
antagonists be administered beyond 24 hours after chemotherapy 
to prevent delayed emesis? Systematic re-evaluation of clinical 
evidence and drug cost implications. J Clin Oncol 2005; 23: 1289-94.
30. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, et al. 
Palonosetron triggers 5-HT(3) receptor internalization and causes 
prolonged inhibition of receptor function. Eur J Pharmacol 2010; 
626: 193-9.
